142 related articles for article (PubMed ID: 11769772)
1. Directly observed treatment for multidrug-resistant tuberculosis: an economic evaluation in the United States of America and South Africa.
Wilton P; Smith RD; Coast J; Millar M; Karcher A
Int J Tuberc Lung Dis; 2001 Dec; 5(12):1137-42. PubMed ID: 11769772
[TBL] [Abstract][Full Text] [Related]
2. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
Pablos-Mendez A; Gowda DK; Frieden TR
Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
[TBL] [Abstract][Full Text] [Related]
3. Epidemiological and cost analysis of multidrug-resistant tuberculosis in Oman.
Mohammadi A; Nassor ZS; Behlim T; Mohammadi E; Govindarajan R; Al Maniri A; Smego RA
East Mediterr Health J; 2008; 14(6):1240-5. PubMed ID: 19161099
[TBL] [Abstract][Full Text] [Related]
4. Latent tuberculosis infection in children: a call for revised treatment guidelines.
Finnell SM; Christenson JC; Downs SM
Pediatrics; 2009 Mar; 123(3):816-22. PubMed ID: 19255008
[TBL] [Abstract][Full Text] [Related]
5. In vitro drug resistance and response to therapy in pulmonary tuberculosis patients under a DOTS programme in south India.
Aparna SB; Reddy VC; Gokhale S; Moorthy KV
Trans R Soc Trop Med Hyg; 2009 Jun; 103(6):564-70. PubMed ID: 19243801
[TBL] [Abstract][Full Text] [Related]
6. Patient and family costs associated with tuberculosis, including multidrug-resistant tuberculosis, in Ecuador.
Rouzier VA; Oxlade O; Verduga R; Gresely L; Menzies D
Int J Tuberc Lung Dis; 2010 Oct; 14(10):1316-22. PubMed ID: 20843424
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of an alternative tuberculosis management strategy for permanent farm dwellers in South Africa amidst health service contraction.
Clarke M; Dick J; Bogg L
Scand J Public Health; 2006; 34(1):83-91. PubMed ID: 16449048
[TBL] [Abstract][Full Text] [Related]
8. Is DOTS-plus a feasible and cost-effective strategy?
Garner P; Alejandria M; Lansang MA
PLoS Med; 2006 Sep; 3(9):e350. PubMed ID: 16968122
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of different treatment strategies for tuberculosis in Egypt and Syria.
Vassall A; Bagdadi S; Bashour H; Zaher H; Maaren PV
Int J Tuberc Lung Dis; 2002 Dec; 6(12):1083-90. PubMed ID: 12546116
[TBL] [Abstract][Full Text] [Related]
10. Community-based management of multidrug-resistant tuberculosis in South Africa.
Bekker LG; Wood R
Int J Tuberc Lung Dis; 2010 Apr; 14(4):379. PubMed ID: 20202291
[No Abstract] [Full Text] [Related]
11. Drug-resistant tuberculosis. In South Africa, XDR TB and HIV prove a deadly combination.
Koenig R
Science; 2008 Feb; 319(5865):894-7. PubMed ID: 18276863
[No Abstract] [Full Text] [Related]
12. Cost-effective control of drug-resistant TB: listening to other voices.
Portero JL; Rubio M
PLoS Med; 2006 Dec; 3(12):e542. PubMed ID: 17194207
[No Abstract] [Full Text] [Related]
13. Multidrug-resistant TB in the Philippines: totem and taboo.
Portero JL; Rubio M
PLoS Med; 2006 Dec; 3(12):e539; author reply e549. PubMed ID: 17194204
[No Abstract] [Full Text] [Related]
14. Cost of treatment for multidrug-resistant tuberculosis in South Korea.
Kang YA; Choi YJ; Cho YJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
Respirology; 2006 Nov; 11(6):793-8. PubMed ID: 17052310
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of individualised treatment for multidrug-resistant tuberculosis before DOTS-plus.
Ollé-Goig JE; Sandy R
Int J Tuberc Lung Dis; 2005 Jul; 9(7):765-70. PubMed ID: 16013772
[TBL] [Abstract][Full Text] [Related]
16. Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru.
Chavez Pachas AM; Blank R; Smith Fawzi MC; Bayona J; Becerra MC; Mitnick CD
Int J Tuberc Lung Dis; 2004 Jan; 8(1):52-8. PubMed ID: 14974746
[TBL] [Abstract][Full Text] [Related]
17. [The cost of treatment in new case and multidrug resistant case in pulmonary tuberculosis].
Kizkin O; Hacievliyagil SS; Türker G; Günen H
Tuberk Toraks; 2003; 51(4):410-5. PubMed ID: 15143390
[TBL] [Abstract][Full Text] [Related]
18. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment.
Ormerod LP
Br Med Bull; 2005; 73-74():17-24. PubMed ID: 15956357
[TBL] [Abstract][Full Text] [Related]
19. Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia.
Riekstina V; Leimane V; Holtz TH; Leimans J; Wells CD
Int J Tuberc Lung Dis; 2007 May; 11(5):585-7. PubMed ID: 17439686
[TBL] [Abstract][Full Text] [Related]
20. Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
Coker R
Int J Tuberc Lung Dis; 2002 Aug; 6(8):649-50. PubMed ID: 12150473
[No Abstract] [Full Text] [Related]
[Next] [New Search]
